Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05296837 · ClinicalTrials.gov registry record · Phase 4
Ocular Rosacea Biome Study
A Phase 4 study of Antimicrobial Resistance and Ocular Rosacea, sponsored by University of California, San Francisco.
- Active
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT05296837: Active Phase 4 study of Antimicrobial Resistance and Ocular Rosacea, sponsored by University of California, San Francisco.
NCT05296837 is a Phase 4 study of Antimicrobial Resistance and Ocular Rosacea that is active but no longer recruiting, run by University of California, San Francisco. The registered enrollment target is 50 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05296837, a Phase 4 study of Antimicrobial Resistance and Ocular Rosacea, is active but no longer recruiting, sponsored by University of California, San Francisco.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Ocular rosacea is an inflammatory disease of the eyelids and ocular surface. Like the facial disease, the ocular condition is chronic and recurrent. Sequelae of ocular rosacea vary from mild to severe. Ocular rosacea may cause chronic eye redness, blepharitis, recurrent chalazia, dry eye, corneal erosion, corneal vascularization, and corneal ulceration. Rosacea affecting the cornea can result in vision loss. Prescription eye drops and ointments can be used topically to control mild ocular rosacea. However, severe disease, or rosacea that is not well controlled with local treatments is treated systemically. The most commonly used systemic treatment for rosacea is the bacteriostatic antibiotic doxycycline. Rosacea treatment doses of doxycycline vary widely. Treatment-dose doxycycline for systemic infections is 100mg twice a day. However, as rosacea is considered an inflammatory disease, doxycycline is often dosed at what is termed, sub-microbial dose doxycycline (SDD). Initially introduced in the oral medicine literature, SDD are doses 40mg and lower because systemic administration at this dose does not appear to alter the oral mucosa flora or increase resistance rates when given long-term for periodontal disease. Whereas 100mg doxycycline, even when given short term, may increase the percentage of culturable nasopharyngeal flora that is resistant to doxycycline. The FDA does not categorize SDD an antibiotic, stating this dosing is expected to exhibit only anti-inflammatory activity.
Primary Outcome
The frequency of AMR genetic determinants in rectal swab samples between arms will be compared, correcting for baseline
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Doxycycline 40 MG ( 20mg twice daily)
- DRUG Doxycycline 200 MG ( 100 mg twice daily)
Study Locations (1)
California
- University of California, San Farncisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-06-22 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 4 |
What the registry record for NCT05296837 still lists
NCT05296837 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with Antimicrobial Resistance appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05296837 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05296837 about?
NCT05296837 is a clinical study titled "Ocular Rosacea Biome Study". Ocular rosacea is an inflammatory disease of the eyelids and ocular surface. Like the facial disease, the ocular condition is chronic and recurrent. Sequelae of ocular rosacea vary from mild to severe. Ocular rosacea may cause chronic eye redness, blepharitis, recurrent chalazia, dry eye, corneal er...
What is the current status of trial NCT05296837?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2023-06-22. Estimated completion is 2026-07-31.
What conditions does trial NCT05296837 study?
This clinical trial studies the following conditions: Antimicrobial Resistance, Ocular Rosacea.
What interventions are being tested in trial NCT05296837?
The interventions under investigation include: Placebo (DRUG), Doxycycline 40 MG ( 20mg twice daily) (DRUG), Doxycycline 200 MG ( 100 mg twice daily) (DRUG).
Who is sponsoring clinical trial NCT05296837?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05296837 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Antimicrobial Resistance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05296837's enrollment target sits among peer trials
50 1255th of 2000 higher than 679 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI